Tivic Health Reports Findings of Clinical Optimization Trial of Non-Invasive Cervical Vagus Nerve Stimulation (ncVNS) The study demonstrated that personalizing the stimulation parameters to each user dramatically enhance

Tivic Health Reports Findings of Clinical

Optimization Trial of Non-Invasive Cervical Vagus Nerve Stimulation (ncVNS)

The study demonstrated that personalizing

the stimulation parameters to each user dramatically enhanced autonomic effects

Calif. - November 13, 2025 - Tivic Health Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, announced

today it has optimized key device and treatment parameters including frequency, amplitude, electrode positioning, and duration of stimulation

as a result of its collaborative study with The Feinstein Institutes for Medical Research at Northwell Health.

measurements taken before, during, and after ncVNS treatment found the following:

studies of non-invasive VNS devices have reported mixed results for autonomic nervous system changes, Tivic's study demonstrated that

specific parameters could reproducibly impact outcomes.

makes our findings so compelling is that they advance the field of neurostimulation by underscoring the importance of stimulation frequency

personalization, laterality and placement of stimulation electrodes, and duration of treatment," stated Jennifer Ernst, CEO

of Tivic Health. "While these results were in healthy subjects, this data combined with our past studies suggest our ncVNS approach

may have clinical utility in several very large patient populations including ischemic stroke, post-traumatic stress disorder, and inflammatory

diseases, among others."

"Our mission is to harness the immune system to improve clinical outcomes and save lives. We are energized by these results and we

believe that this new data will enable us to unlock valuable new opportunities that can be developed either in house or with partners

as funding is allocated across a growing pipeline of late-, mid- and early stage product candidates."

Tivic Health Systems, Inc.

dual platform utilizes the body's biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the

biologics compounds activate an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across

systems impacted by radiation and age. The company's lead drug candidate, Entolimod for acute radiation syndrome, is a novel

TLR5 agonist that has been granted Fast Track and Orphan Drug designations and is in late-stage development.

bioelectronic program is developing a novel, non-invasive medical device designed to target the neural pathways implicated in

many prevalent and debilitating diseases. Early trials show promising signals that Tivic's approach may regulate specific biologic

responses, and the company believes its early-stage vagus nerve stimulation device has the potential to deliver clinical outcomes similar

to or better than those of surgically implanted devices. To learn more about Tivic, visit: https://ir.tivichealth.com.

release may contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements,

other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements

contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate,"

"could," "estimate," "expect," "intend," "seek," "may," "might,"

"plan," "potential," "predict," "project," "target," "aim," "should,"

"will," "would," or the negative of these words or other similar expressions, although not all forward-looking

statements contain these words. Forward-looking statements are based on Tivic Health Systems Inc.'s current expectations and are

subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements

are based on assumptions as to future events that may not prove to be accurate, including as a result of interactions with and guidance

from the FDA and other regulatory authorities; changes to the company's relationship with the its partners; timing and success

of clinical trials and study results; the indications for which the company's ncVNS approach may ultimately be found to have clinical

utility based on additional studies and trials; the company's ability to unlock new opportunities for the further development of

its ncVNS platform; the failure to obtain FDA or similar clearances or approvals and noncompliance with FDA or similar regulations; the

company's future development of its ncVNS treatment, Entolimod and Entolasta; changes to the company's business strategy;

regulatory requirements and pathways for approval; the company's ability to successfully commercialize its product candidates in

the future; the potential opportunities that may be available to the company and its product candidates in the future; the company's

need for, and ability to secure when needed, additional working capital; the company's ability to maintain its Nasdaq listing;

and changes in tariffs, inflation, legal, regulatory, political and economic risks. Actual results could differ materially from those

contained in any forward-looking statement as a result of various factors. Accordingly, you are cautioned not to place undue reliance

on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors,

see Tivic Health's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2024, filed

with the SEC on March 21, 2025, under the heading "Risk Factors," as well as the company's subsequent filings with

the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes

no duty to update such information except as required by applicable law.

Hanover International, Inc.

Deanne Eagle or Laura Min Jackson